Recent Antibody Targeting Technologies—A Survey of the Patent Literature

Abstract

The widespread application of antibody therapies has recently become a promising reality. This has come about because of advances in our understanding of the Chemistry and Biology of antibodies, our ability to engineer or create human versions of antibodies directed at specific targets, and our ability to generate large, highly purified quantities of these antibodies for clinical use. With the potential for an increased number of specific target site coming from information garnered from the sequence of the human genome, it seems highly likely that the best is yet to come for antibody-directed drug targeting therapies.